Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 9/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 5/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466553 | 0.94 | AVPR1B (0.44) | AVPR1BAKR1B10GHSRKDM4EMEN1 | |
| SCHEMBL2461959 | 0.92 | AVPR1B (0.40) | AVPR1BGHSRKDM4EMEN1ALDH1A1 | |
| SCHEMBL2456334 | 0.92 | AVPR1B (0.55) | AVPR1BAVPR1A | |
| SCHEMBL12334746 | 0.92 | AVPR1B (0.55) | AVPR1BAVPR1A | |
| SCHEMBL2459891 | 0.90 | AVPR1B (0.45) | AVPR1BAKR1B10GHSRKDM4EMEN1 | |
| SCHEMBL2465136 | 0.88 | AVPR1B (0.46) | AVPR1BAKR1B10GHSRAVPR1A | |
| SCHEMBL2461887 | 0.86 | AVPR1B (0.41) | AVPR1BGHSRKDM4EMEN1ALDH1A1 | |
| SCHEMBL3451949 | 0.86 | AVPR1B (0.56) | AVPR1BAVPR1A | |
| SCHEMBL2457049 | 0.82 | AVPR1B (0.42) | AVPR1BGHSRKDM4EMEN1ALDH1A1 | |
| SCHEMBL2456382 | 0.82 | AVPR1B (0.57) | AVPR1BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | AVPR1B 839/4885AKR1B10 765/4885GHSR 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.